PDS Biotech 10-Q: $5.6M Cash, Going Concern Doubt, Nasdaq Delisting Risk
PDSB is trading near its 52-week low of $0.217 (9.5% above the low) on elevated volume (3.5× avg).
Summary
PDS Biotech's 10-Q reveals $5.6M in cash, a going concern warning, and Nasdaq delisting risk, with accelerated debt repayment triggered if the stock stays below $1.00.
Key Events · Earnings and Guidance · PDSB
-
Going Concern Warning
Management concluded substantial doubt exists about the company's ability to continue as a going concern for at least 12 months, citing $5.6M in cash, no revenue, and ongoing operating losses.
-
Nasdaq Delisting Risk
Stock fell below the $1.00 minimum bid price, triggering a deficiency letter on July 30, 2026. The company has 180 days to regain compliance or face delisting.
-
Debt Acceleration Clause
If the bid price deficiency is not cured within 75 days, the $6M promissory note to YA II PN, Ltd. requires accelerated payments of $2M per installment.
-
Cash Burn and Financing
Cash decreased from $26.7M at year-end to $5.6M at June 30, 2026. The company has a $50M ATM facility but sold only $0.1M under it during Q2.
Analysis · PDSB · Life Sciences
PDS Biotech's Q2 10-Q confirms a $9.8M quarterly net loss and cash of just $5.6M, down from $26.7M at year-end. Management states substantial doubt about the company's ability to continue as a going concern for at least 12 months. The stock is also at risk of Nasdaq delisting after falling below the $1.00 minimum bid price, with a 180-day grace period to regain compliance. If the bid price deficiency is not cured within 75 days, the company must accelerate repayment of its $6M promissory note to YA II PN, Ltd. at $2M per installment. The company has a $50M ATM facility available but has sold only $0.1M under it, and its strategic refocus on PDS0301 after discontinuing the PDS0101 Phase 3 trial leaves it dependent on a single asset with no near-term revenue.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 41% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $0.22 to $1.55. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.